RELIEF Therapeutics Holding AG Logo

RELIEF Therapeutics Holding AG

ISIN: CH0100191136 | Ticker: RLF | LEI: 506700IT19260EVD7916
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Switzerland

About RELIEF Therapeutics Holding AG

Company Description

Relief is a biopharmaceutical company whose objective is to provide patients with therapeutic RELIEF in serious diseases with high unmet medical need.

We focus on clinical-stage programs based on molecules with a history of clinical use (well-established safety and tolerability) and either initial human activity or efficacy data (proof of concept) or a strong scientific rationale. This allows us to identify molecules where clinical development can be swift (trials with evaluation windows of weeks or months) and cost effective. Our lead compound is RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action, for respiratory indications. The development program currently is focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. These are two diseases for which an unmet medical need exists. Clinical development opportunities of RLF-100™ for other indications in both acute and chronic lung diseases are being evaluated.

Year founded


Served area



Avenue de Sécheron 15, 1202 Genève – Switzerland

Filings & Publications

Sign up and we will give you access!

Insider Trades

Sign up and we will give you access!

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.